364 related articles for article (PubMed ID: 22768972)
1. Acetylcholinesterase inhibitors: a patent review (2008 - present).
Pohanka M
Expert Opin Ther Pat; 2012 Aug; 22(8):871-86. PubMed ID: 22768972
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors: a patent review (2007 - 2011).
de los Ríos C
Expert Opin Ther Pat; 2012 Aug; 22(8):853-69. PubMed ID: 22764681
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
McHardy SF; Wang HL; McCowen SV; Valdez MC
Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
5. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection.
Singh M; Kaur M; Kukreja H; Chugh R; Silakari O; Singh D
Eur J Med Chem; 2013; 70():165-88. PubMed ID: 24148993
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterases, a target of pharmacology and toxicology.
Pohanka M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Sep; 155(3):219-29. PubMed ID: 22286807
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
da Silva CH; Campo VL; Carvalho I; Taft CA
J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
[TBL] [Abstract][Full Text] [Related]
9. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
10. Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease.
El-Malah A; Gedawy EM; Kassab AE; Salam RM
Arch Pharm (Weinheim); 2014 Feb; 347(2):96-103. PubMed ID: 24343873
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
12. Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
Musilek K; Komloova M; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K
Eur J Med Chem; 2011 Feb; 46(2):811-8. PubMed ID: 21236521
[TBL] [Abstract][Full Text] [Related]
13. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B; Singh N
Bioorg Med Chem; 2012 Feb; 20(3):1175-80. PubMed ID: 22257528
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
15. Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis.
Galdeano C; Coquelle N; Cieslikiewicz-Bouet M; Bartolini M; Pérez B; Clos MV; Silman I; Jean L; Colletier JP; Renard PY; Muñoz-Torrero D
Molecules; 2018 Mar; 23(3):. PubMed ID: 29534488
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
Szymański P; Janik A; Zurek E; Mikiciuk-Olasik E
Pharmazie; 2011 Jun; 66(6):399-403. PubMed ID: 21699076
[TBL] [Abstract][Full Text] [Related]
17. In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity.
da Silva VB; de Andrade P; Kawano DF; Morais PA; de Almeida JR; Carvalho I; Taft CA; da Silva CH
Future Med Chem; 2011 Jun; 3(8):947-60. PubMed ID: 21707398
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
[TBL] [Abstract][Full Text] [Related]
19. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
Musilek K; Komloova M; Zavadova V; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K; Jung YS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1763-6. PubMed ID: 20138518
[TBL] [Abstract][Full Text] [Related]
20. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Castro A; Martinez A
Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
